Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics

Open Access
Publisher Website
Google Scholar
Abstract
The completion of the human genome project and the burgeoning use of genomic, transcriptional profiling, and proteomic technologies to investigate DNA, RNA, and protein levels in tumors, serum, plasma, and urine offer the exciting potential of identifying novel and effective cancer-specific screening markers. If the markers are secreted or released from tumor cells and migrate to serum, plasma, urine, or other accessible sites, they may be useful as screening markers either alone or in combination with currently identified tumor markers or screening approaches. Thus, these technologies potentially provide for a rapid advance in the identification of novel tumor markers comparable to that initiated by the introduction of monoclonal antibody technology.